☆ 4.7 Article

Confirmation of CD19+ B-Lymphocyte Depletion Prior to Intake of the Second Dose of Ocrelizumab in Multiple Sclerosis Patients

BIOMEDICINES (2023)

Related references

Note: Only part of the references are listed.

Review Pharmacology & Pharmacy

Ocrelizumab: A Review in Multiple Sclerosis

Yvette N. Lamb

Summary: Multiple sclerosis is a chronic neurodegenerative disease where Ocrelizumab, a monoclonal antibody, has been proven to be a highly effective and convenient treatment option for patients with relapsing forms of MS and primary progressive MS. It reduces relapse rates, delays disability progression, and has shown no new safety signals with long-term use.

DRUGS (2022)

Add to Collection

Review Clinical Neurology

Anti-CD20 therapies for multiple sclerosis: current status and future perspectives

Monica Margoni et al.

Summary: Multiple sclerosis is a chronic disease affecting the central nervous system, and recent advancements in immune pathophysiology have led to the identification of selective B-cell-depleting therapies like anti-CD20 monoclonal antibodies, which have shown strong efficacy and safety in treating MS. This has expanded the therapeutic options for both relapsing and progressive MS patients, highlighting the important role of B cells in the disease process.

JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab

Mario Habek et al.

Summary: This study investigated the influence of immunoglobulin levels on the rate of infections in people with multiple sclerosis (pwMS) treated with ocrelizumab. The results showed that female sex, older age, and smaller drop in IgM levels were associated with increased risk of infection and hospitalization, while longer disease duration increased the risk of COVID-19.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Add to Collection

Article Clinical Neurology

Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells

Gianmarco Abbadessa et al.

Summary: This study investigated the effect of Ocrelizumab on lymphocyte subtypes in multiple sclerosis (MS) patients and compared the differences between patients with and without lymphopenia. The results showed that Ocrelizumab reduced absolute lymphocyte count (ALC) and particularly impacted CD8 T cells. The decrease of CD8 T cells was more significant in patients with lymphopenia. This has important implications for understanding the clinical response and risk of viral infections associated with Ocrelizumab.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Add to Collection

Article Medicine, General & Internal

Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study

Roberta Lanzillo et al.

Summary: The study demonstrates that early ocrelizumab treatment is effective in modifying disability accrual in MS patients.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Clinical Neurology

Molecular Mechanisms of Immunosenescene and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis

Oceane Perdaens et al.

Summary: Aging is characterized by cellular senescence and chronic inflammation called inflammaging, both of which contribute to increased incidence of diseases and reduced response to vaccination. This article aims to review the markers and mechanisms of immunosenescence and their relevance to understanding multiple sclerosis (MS) pathogenesis. It will also discuss the age-related changes in the innate and adaptive immune system in MS and other autoimmune diseases, as well as the impact of immunosenescence on disease progression and the efficacy of current treatments.

FRONTIERS IN NEUROLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

Ekaterina Gibiansky et al.

Summary: The study assessed the pharmacokinetics and pharmacodynamics of ocrelizumab in patients with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). Results showed that the serum concentration of ocrelizumab was accurately described by a 2-compartment model with time-dependent clearance, with body weight as the main covariate. B-cell depletion in blood was also found to be greater with higher exposure to ocrelizumab.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Clinical Neurology

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain

Angel P. Sempere et al.

Summary: This study retrospectively observed the clinical and MRI data of patients with primary progressive multiple sclerosis (PPMS) and relapsing multiple sclerosis (RMS) receiving ocrelizumab, showing that most patients remained free from symptom activity after treatment. Ocrelizumab was well-tolerated and effective in clinical practice.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

Jose Fernandez-Velasco et al.

Summary: Ocrelizumab induced changes in immune cell distribution in patients with primary progressive MS, reducing inflammatory cells and leading to a decrease in sNfL levels.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

Add to Collection

Article Multidisciplinary Sciences

Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis

Ben J. E. Raveney et al.

Summary: This study identified a subset of cytotoxic CD4(+) T cells expressing Eomes, known as Eomes(+) Th cells, that are crucially involved in the pathogenesis of secondary progressive MS (SPMS). Eomes levels could act as a biomarker to predict disease worsening in SPMS patients with over 80% accuracy. These findings have significant implications for SPMS biomarkers and potential therapeutic targets.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Review Cell Biology

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects

Stefanie Fischer et al.

Summary: While the detailed pathogenesis of multiple sclerosis (MS) remains unclear, a range of disease-modifying therapies (DMTs) are available. A common side effect of almost every MS therapeutic agent is lymphopenia, which can have both beneficial and limiting effects on treatment. Understanding the mechanism of action of the selected agent is essential for comprehending treatment-associated changes in white blood cell counts and monitoring outcomes.

CELLS (2021)

Add to Collection

Article Clinical Neurology

Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis

Nicola Capasso et al.

Summary: Both rituximab and ocrelizumab similarly decrease B-cell levels in peripheral blood of multiple sclerosis patients, but ocrelizumab shows a more pronounced reduction in CD4 and CD8 T lymphocytes. The two antibodies have comparable effects on reducing lymphocyte count, and the broader immunomodulatory effect of ocrelizumab needs to be confirmed and correlated with long-term clinical efficacy.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Review Cell Biology

Macrophages and Autoantibodies in Demyelinating Diseases

Haruki Koike et al.

Summary: Myelin phagocytosis by macrophages is a key feature of demyelinating diseases, with the discovery of specific autoantibodies aiding in the identification of distinct disease entities, though the underlying mechanisms remain unclear. Macrophages appear to selectively target specific sites on myelinated fibers for demyelination, indicating the importance of localized components in initiating myelin phagocytosis.

CELLS (2021)

Add to Collection

Article Clinical Neurology

Proinflammatory CD20+ T Cells are Differentially Affected by Multiple Sclerosis Therapeutics

Corinna Quendt et al.

Summary: The frequency and effects of CD20(+) T cells in patients with multiple sclerosis vary depending on the treatment method, with some extinguishing the cells while others only reducing their abundance as part of a broader T cell suppressive capacity.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Review Clinical Neurology

B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies

Maria T. Cencioni et al.

Summary: This Review discusses the roles of B cells in multiple sclerosis, highlighting the involvement of B cells in disease pathogenesis and the potential mechanisms underlying the abnormalities in B cell function in MS.

NATURE REVIEWS NEUROLOGY (2021)

Add to Collection

Letter Clinical Neurology

Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient

Mariano Marrodan et al.

NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Clinical Neurology

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

Stephen L. Hauser et al.

Summary: This study reports the safety of ocrelizumab treatment for up to 7 years in patients with multiple sclerosis, showing a consistent and manageable safety profile without emerging safety concerns. The rates of the most common serious adverse events, including serious infections and malignancies, were consistent with epidemiologic data ranges. Additionally, long-term, continuous treatment with ocrelizumab was associated with a favorable safety profile in a heterogeneous multiple sclerosis population.

NEUROLOGY (2021)

Add to Collection

Article Environmental Sciences

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab

Gianmarco Abbadessa et al.

Summary: The kinetics of B cell repopulation in multiple sclerosis patients treated with Ocrelizumab have a significant impact on clinical and radiological outcomes, with baseline circulating immune assets also playing a role in influencing repopulation kinetics. Tailoring Ocrelizumab dosage based on CD19 cell counts at baseline may help achieve complete disease control for all patients.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)

Add to Collection

Review Health Care Sciences & Services

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology

Chiara Rosa Mancinelli et al.

Summary: Selective B-cell depleting therapy, represented by ocrelizumab targeting CD20+ B-cells, has shown significant success in treating multiple sclerosis, proving to be highly effective in suppressing disease activity and even slowing disability progression. Its efficacy and safety have been widely demonstrated in clinical trials.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2021)

Add to Collection

Article Clinical Neurology

Severe Delayed-Onset Neutropenia Induced by Ocrelizumab

Jonatha Baird-Gunning et al.

Summary: Ocrelizumab, an anti-CD20 monoclonal antibody, has been shown to slow disability progression in primary progressive multiple sclerosis. However, a rare complication associated with ocrelizumab is severe late-onset neutropenia, which requires prompt medical attention if patients develop fever.

NEUROHOSPITALIST (2021)

Add to Collection

Article Medicine, Research & Experimental

Myelin-specific CD8(+) T cells exacerbate brain inflammation in CNS autoimmunity

Catriona A. Wagner et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Review Virology

Role of Viruses in the Pathogenesis of Multiple Sclerosis

Rachael E. Tarlinton et al.

VIRUSES-BASEL (2020)

Add to Collection

Review Infectious Diseases

Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?

Mena Al-Ani et al.

INFECTION AND DRUG RESISTANCE (2020)

Add to Collection

Review Clinical Neurology

Multiple sclerosis - a review

R. Dobson et al.

EUROPEAN JOURNAL OF NEUROLOGY (2019)

Add to Collection

Article Cell Biology

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients

Stefan Gingele et al.

CELLS (2019)

Add to Collection

Article Cell Biology

Subsets of activated monocytes and markers of inflammation in incipient and progressed multiple sclerosis

Mikkel Carstensen Gjelstrup et al.

IMMUNOLOGY AND CELL BIOLOGY (2018)

Add to Collection

Article Clinical Neurology

The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+T lymphocytes and B cells

Joana Machado-Santos et al.

BRAIN (2018)

Add to Collection

Article Multidisciplinary Sciences

Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility

Abigail E. Russi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)

Add to Collection

Review Clinical Neurology

Multiple Sclerosis

Bassem I. Yamout et al.

SEMINARS IN NEUROLOGY (2018)

Add to Collection

Review Clinical Neurology

Ocrelizumab: a new milestone in multiple sclerosis therapy

Patricia Mulero et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)

Add to Collection

Article Clinical Neurology

New insights into the burden and costs of multiple sclerosis in Europe

Gisela Kobelt et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

S. L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Clinical Neurology

New insights into the burden and costs of multiple sclerosis in Europe

Gisela Kobelt et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Review Hematology

How I diagnose and treat neutropenia

David C. Dale

CURRENT OPINION IN HEMATOLOGY (2016)

Add to Collection

Article Genetics & Heredity

Class II HLA interactions modulate genetic risk for multiple sclerosis

Loukas Moutsianas et al.

NATURE GENETICS (2015)

Add to Collection

Review Immunology

The role of natural killer cells in multiple sclerosis and their therapeutic implications

Coralie Chanvillard et al.

FRONTIERS IN IMMUNOLOGY (2013)

Add to Collection

Review Biochemistry & Molecular Biology

Role of CD8 T cell subsets in the pathogenesis of multiple sclerosis

A. Saxena et al.

FEBS LETTERS (2011)

Add to Collection

Article Cell Biology

Splenic natural killer cell activity in two models of experimental neurodegenerative diseases

Yassin Al-Falahi et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)

Add to Collection

Review Clinical Neurology

B cells as therapeutic targets in autoimmune neurological disorders

Marinos C. Dalakas

NATURE CLINICAL PRACTICE NEUROLOGY (2008)

Add to Collection

Review Public, Environmental & Occupational Health

HLA-DR15 haplotype and multiple sclerosis:: A HuGE review

Hollie Schmidt et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)

Add to Collection

Article Clinical Neurology

Immunopathology of secondary-progressive multiple sclerosis

JW Prineas et al.

ANNALS OF NEUROLOGY (2001)

Add to Collection

Article Immunology

IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-γ by NK cells

FD Shi et al.

JOURNAL OF IMMUNOLOGY (2000)

Add to Collection

Article Immunology

Effect of IFNβ and anti-IFNβ antibodies on NK cells in multiple sclerosis patients

P Perini et al.

JOURNAL OF NEUROIMMUNOLOGY (2000)

Add to Collection

Article Immunology

Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the central nervous system and modulates experimental allergic encephalomyelitis

A Pagenstecher et al.

JOURNAL OF IMMUNOLOGY (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.